DALLAS - s4story -- The federal multidistrict litigation consolidating hair relaxer cancer lawsuits (MDL No. 3060, N.D. Illinois) has surpassed 9,500 pending cases, making it one of the fastest-growing mass tort dockets in recent memory. As bellwether trial selections move forward, advocates and legal resources are working to ensure that affected women — particularly Black women, who are statistically the most impacted demographic — understand their rights and options.

The litigation stems largely from a landmark 2022 study published in the *Journal of the National Cancer Institute* by researchers at the National Institutes of Health (NIH). The study, which tracked more than 33,000 women over more than a decade as part of the Sister Study cohort, found that women who used chemical hair straighteners or relaxers more than four times per year faced approximately 2.55 times the risk of developing uterine cancer compared to non-users. The findings were described by researchers as "concerning" given the disproportionate use of these products among Black women in the United States.

More on S For Story

• Atlanta Teen Author and #1 Top New Release Sarai Lokey Takes "Holy Rebel" Straight To The Top!
• The Inner Power of Emotional Self-Leadership
• Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
• eBook Publishing Services in USA California Book Publishers Helps Authors Turn Ideas into Successful
• Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause

Uterine cancer is the most common gynecologic cancer in America, and its incidence has been rising sharply — particularly among Black women, who are already more likely to be diagnosed at later stages and face worse outcomes. Researchers and public health advocates have pointed to chemical hair relaxers — widely marketed for decades with limited safety scrutiny — as a potentially significant environmental contributor.

Products named in litigation include relaxers sold under brand names such as Dark & Lovely, ORS Olive Oil, Just for Me, and others manufactured by companies including L'Oréal USA, Revlon, and Strength of Nature. Defendants have contested liability, but the volume of scientifically supported claims has sustained judicial consolidation and advancing trial timelines.

Bellwether trials in MDL 3060 are expected to provide critical signal for how juries may respond to the underlying science and the marketing histories of the named products — outcomes that will likely shape settlement discussions affecting thousands of plaintiffs.

More on S For Story

• Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
• eBook Ghostwriting Services in USA: Noble Book Publishers Helps Authors Turn Ideas into Bestsellers
• Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
• Over 98% of crypto owners globally don't declare taxes, new report find
• TicTac Group acquires French EdTech company Distrisoft

Women who used chemical hair relaxers regularly and have since been diagnosed with uterine cancer, ovarian cancer, or other reproductive conditions are encouraged to review their legal options. A free case review resource is available at https://relaxercancer.com, offering plain-language information on eligibility, the current state of litigation, and next steps.

"This litigation represents a long-overdue reckoning with products that were marketed aggressively to Black women without adequate safety testing," said a spokesperson for the resource. "The science is clear. Women deserve to know where the cases stand."